ARCHER-1050

NCT01774721 📎

Regimen

Experimental
dacomitinib
Control
gefitinib

Population

EGFR-mut advanced NSCLC, no brain mets

Key finding

mPFS 14.7 vs 9.2 mo, HR 0.59 (0.47-0.74); 2nd-gen TKI improves PFS over 1st-gen

Source: PMID 28958502

Timeline

  • Enrollment start: 2013-05-09 📎

Guideline citations

  • NCCN NSCLC Version 5.2026 (p.112)
  • CSCO NSCLC 2025 ⚠️ OCR source